Blinatumomab
Bispecific CD19-directed CD3-directed T Cell Engager — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: blincyto, MEDI-538, MT-103
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Blinatumomab is a drug in the Bispecific CD19-directed CD3-directed T Cell Engager class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as CD19-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions. DrugCentral lists 2 molecular targets, including CD19 and CD3E|CD3G|CD3D. Recorded indications include Pre B-cell acute lymphoblastic leukemia.
- Drug class: Bispecific CD19-directed CD3-directed T Cell Engager.
- Mechanism of action: CD19-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions.
- Molecular targets: CD19 and CD3E|CD3G|CD3D (2 listed in DrugCentral).
- Indications: Pre B-cell acute lymphoblastic leukemia.
- ATC code: L01FX07 (Other monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Pre B-cell acute lymphoblastic leukemia
Mechanism & targets
| Mechanism of action (MoA) | CD19-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions |
|---|---|
| Established pharmacologic class | Bispecific CD19-directed CD3-directed T Cell Engager |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| B-lymphocyte antigen CD19 | CD19 | other | Kd 9.00 |
| T-cell surface glycoprotein CD3 | CD3E|CD3G|CD3D | other | Kd 7.00 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-09-21 | PMDA | — | Amgen Astellas Biopharma KK | |
| 2015-11-23 | EMA | — | Amgen Europe B.V. | Yes |
| 2014-12-03 | FDA | — | AMGEN |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FX07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CD19 · Testing Required
- EMA label: ABL1, BCR
- FDA label: CD19 · Testing Required
- FDA label: ABL1, BCR
- HCSC label: ABL1, BCR
- HCSC label: CD19 · Testing Required
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Acute lymphocytic leukaemia recurrent | 4844.1 |
| Cytokine release syndrome | 3397.0 |
| Neurotoxicity | 1694.5 |
| Leukaemic infiltration extramedullary | 1171.9 |
| Central nervous system leukaemia | 1060.9 |
| Pyrexia | 866.8 |
| Immune effector cell-associated neurotoxicity syndrome | 619.9 |
| Blast cell count increased | 486.4 |
| Acute lymphocytic leukaemia refractory | 431.3 |
| Minimal residual disease | 420.0 |
| Therapy non-responder | 321.5 |
| Acute graft versus host disease | 314.4 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 853426-35-4 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Blinatumomab used for?
DrugCentral lists the following indications for Blinatumomab: Pre B-cell acute lymphoblastic leukemia.
How does Blinatumomab work?
Blinatumomab is classified as CD19-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions; its molecular targets in DrugCentral include CD19 and CD3E|CD3G|CD3D.
When was Blinatumomab first approved?
Blinatumomab was first approved by the FDA in 2014.
What drug class does Blinatumomab belong to?
Blinatumomab is in the Bispecific CD19-directed CD3-directed T Cell Engager class.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4915 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1742992 — compound record and bioactivity
- DrugBank DB09052 — drug record
- FDA UNII 4FR53SIF3A — substance identity
- DailyMed: FDA labels for Blinatumomab — current prescribing information (label search)
- UniProt P15391 (CD19) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.